Balaxi Pharmaceuticals (NSE:BALAXI) Accounts Payable: ₹212 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:BALAXI Balaxi Pharmaceuticals Ltd NSE:BALAXI
63 GF Score
Price ₹24.02
GF Value ₹69.40
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is Balaxi Pharmaceuticals Accounts Payable?

Balaxi Pharmaceuticals NSE:BALAXI +1.48% 63 Accounts Payable is ₹212 Mil as of Mar. 2026. GuruFocus rates NSE:BALAXI with a GF Score™ of 63/100 and a GF Value™ of ₹69.40 (Possible Value Trap). The stock has 5 warning signs investors should review.

Balaxi Pharmaceuticals's Accounts Payable for the quarter that ended in Mar. 2026 was ₹212 Mil.

Balaxi Pharmaceuticals's quarterly Accounts Payable declined from Sep. 2025 (₹195 Mil) to Dec. 2025 (₹0 Mil) but then increased from Dec. 2025 (₹0 Mil) to Mar. 2026 (₹212 Mil).

Balaxi Pharmaceuticals's annual Accounts Payable declined from Mar. 2024 (₹290 Mil) to Mar. 2025 (₹162 Mil) but then increased from Mar. 2025 (₹162 Mil) to Mar. 2026 (₹212 Mil).

Balaxi Pharmaceuticals Accounts Payable Related Terms

Balaxi Pharmaceuticals Accounts Payable Historical Data

* Premium members only.

The historical data trend for Balaxi Pharmaceuticals's Accounts Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Balaxi Pharmaceuticals Accounts Payable Chart

Balaxi Pharmaceuticals Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Accounts Payable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 491.15 345.19 290.38 161.78 212.08

Balaxi Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Accounts Payable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 161.78 0.00 195.47 0.00 212.08
NSE:BALAXI
63GF Score
Balaxi Pharmaceuticals Ltd NSE:BALAXI
Accounts Payable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Balaxi Pharmaceuticals Accounts Payable Calculation

Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.

Frequently Asked Questions Learn more about Accounts Payable →
What does a Accounts Payable of ₹212 Mil mean?
Balaxi Pharmaceuticals (NSE:BALAXI) has a Accounts Payable of ₹212 Mil as of Mar. 2026. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Balaxi Pharmaceuticals and its competitors.
Is Balaxi Pharmaceuticals' Accounts Payable too high?
Balaxi Pharmaceuticals' current Accounts Payable is ₹212 Mil. Overall, Balaxi Pharmaceuticals has a GF Score™ of 63/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Balaxi Pharmaceuticals' Accounts Payable compare to ZTS and UTHR?
Balaxi Pharmaceuticals' Accounts Payable of ₹212 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accounts Payable for a Drug Manufacturers company?
A good Accounts Payable depends on the Drug Manufacturers industry context. However, Accounts Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accounts Payable mean?
A high Accounts Payable can signal that a stock is expensive relative to its fundamentals. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Balaxi Pharmaceuticals and its competitors. Balaxi Pharmaceuticals's current Accounts Payable is ₹212 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Balaxi Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Balaxi Pharmaceuticals (NSE:BALAXI) is currently considered Possible Value Trap. The stock's GF Value™ is ₹69.40, compared to a current price of ₹24.02 — trading 65.4% below its estimated fair value. The current Accounts Payable is ₹212 Mil. Balaxi Pharmaceuticals' overall GF Score™ is 63/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accounts Payable calculated?
Accounts Payable is calculated from a company's financial statements. For Balaxi Pharmaceuticals (NSE:BALAXI), the current Accounts Payable is ₹212 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Balaxi Pharmaceuticals (NSE:BALAXI) Overvalued in 2026?

Based on GuruFocus' analysis, Balaxi Pharmaceuticals stock appears to be undervalued. The current stock price of ₹24.02 is trading 65.4% below its estimated GF Value™ of ₹69.40. GuruFocus considers Balaxi Pharmaceuticals to be Possible Value Trap.

Key valuation signals for NSE:BALAXI:

  • Accounts Payable: ₹212 Mil
  • GF Value™: ₹69.40 vs. price of ₹24.02 (65.4% below fair value)
  • GF Score™: 63/100 with 5 warning signs

No single metric tells the full story. See the NSE:BALAXI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Balaxi Pharmaceuticals Business Description

Address Phase-III, Road No: 81, Jubilee Hills, Plot No.409, H,No: 8-2-293, MAPS Towers, 3rd Floor, Hyderabad, TG, IND, 500 096
Balaxi Pharmaceuticals Ltd is an Indian branded IPR-based pharmaceutical company focusing on frontier markets, with a vast and growing portfolio of prescription and OTC drugs, across multiple therapeutic segments. The company operates in single segment Specialized Wholesale. Geographically it earns key revenue from Guatemala.
63GF Score

Get the complete analysis for NSE:BALAXI

Accounts Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹24.02
Price
₹69.40
GF Value